Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 10,785 Shares of Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 10,785 shares of the company’s stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $55.07, for a total transaction of $593,929.95. Following the completion of the sale, the insider directly owned 282,008 shares of the company’s stock, valued at $15,530,180.56. The trade was a 3.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, October 1st, Carl Dambkowski sold 5,110 shares of Apogee Therapeutics stock. The stock was sold at an average price of $39.80, for a total value of $203,378.00.
• On Wednesday, September 3rd, Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock. The shares were sold at an average price of $37.87, for a total value of $103,195.75.

Apogee Therapeutics Trading Down 0.5%

APGE opened at $54.71 on Friday. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of -13.25 and a beta of 1.50. Apogee Therapeutics Inc. has a 12 month low of $26.20 and a 12 month high of $63.50. The stock has a fifty day moving average price of $45.64 and a 200-day moving average price of $41.37.

Apogee Therapeutics (NASDAQ:APGE) last posted its earnings results on Monday, August 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.10). On average, equities research analysts forecast that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Mizuho initiated coverage on shares of Apogee Therapeutics in a research note on Tuesday, October 21st. They issued an “outperform” rating and a $105.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Wednesday, October 8th. Citigroup reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research report on Thursday, August 28th. BTIG Research reiterated a “buy” rating and issued a $115.00 price target on shares of Apogee Therapeutics in a research note on Thursday, October 9th. Finally, Wedbush restated an “outperform” rating and set a $90.00 price target on shares of Apogee Therapeutics in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $96.50.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Octagon Capital Advisors LP purchased a new stake in shares of Apogee Therapeutics in the 1st quarter valued at $399,752,000. Wellington Management Group LLP lifted its position in Apogee Therapeutics by 21.4% during the first quarter. Wellington Management Group LLP now owns 5,485,754 shares of the company’s stock valued at $204,948,000 after purchasing an additional 968,391 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in Apogee Therapeutics by 77.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,290,464 shares of the company’s stock valued at $56,045,000 after purchasing an additional 563,464 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Apogee Therapeutics by 57.9% in the third quarter. JPMorgan Chase & Co. now owns 1,137,731 shares of the company’s stock valued at $45,202,000 after purchasing an additional 417,161 shares during the last quarter. Finally, Jefferies Financial Group Inc. grew its position in Apogee Therapeutics by 52.3% during the 2nd quarter. Jefferies Financial Group Inc. now owns 642,357 shares of the company’s stock worth $27,898,000 after purchasing an additional 220,561 shares during the period. 79.04% of the stock is owned by institutional investors and hedge funds.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.